Curie.Bio will aim its funds aimed at nurturing early-stage companies advancing towards clinical trials. Credit: FreshVector via Shutterstock.

Biotech startup incubator Curie.Bio has secured $380m in funding for its latest investment pool aimed at nurturing early-stage companies advancing towards clinical trials. 

The fundraising round – which boosts Curie.Bio’s total funds raised to nearly $1bn – specifically targets Series A investments in companies within its accelerator programme, focusing on advancing companies towards clinical proof-of-concept studies. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The Massachusetts-based biotech investor launched with $520m in its pocket in February 2023, with investments from GV, ARCH Venture Partners, and Leaps by Bayer. The investor operates through two parts: one provides seed-stage funding to startups, while the other offers essential services to help advance scientific projects.  

Amid macroeconomic pressures, private biotech venture financing saw a significant downturn in 2022 and 2023. During 2023, funding decreased by 43.2% compared to 2022 and by 52.3% compared to 2021, as investors became more cautious and focused on existing portfolios. 

Curie.Bio was started by Alexis Borisy, Zach Weinberg, and Christoph Lengauer. When it launched last year, the founders highlighted that securing initial funding is scarce in the biotech startup landscape, compared to the tech industry. This requires biotech founders to retain control with minimal support or partner with investors for expertise but give up ownership. According to the fund, Curie.Bio is designed to support founder-led biotechs with extensive guidance beyond typical accelerators.  

Curie.Bio initially supported Forward Therapeutics, Astoria Biologica, Decrypt Biomedicine and Differentiated Therapeutics; however, it now has 20 early-stage therapeutics companies under its belt.  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Forward Therapeutics, Curie.Bio’s first portfolio company, raised $50m in a Series A funding round in November 2023, emerging with drug candidates that target chronic immunological and inflammatory disorders. The Florida-based biopharma progressed from startup to being ready for the clinic within 18 months. 

However, there is renewed optimism according to GlobalData’s recent survey, The State of the Biopharmaceutical Industry 2024. It revealed that 44% of healthcare industry professionals surveyed globally are optimistic or very optimistic about the recovery of biotech funding in the next 12 months.  

GlobalData is the parent company of Pharmaceutical Technology.